In order to elucidate the natural history of @entity1150 ( @entity1150 ), we compared the morbidity and mortality of @entity1 with @entity1150 and that of @entity1 with both @entity1150 and @entity1150 ( @entity1150 ). Between 1993 and 1996, 21 @entity1 presented to our institution with both @entity1150 and @entity1150 (Group 1). During the same time period, 144 @entity1 were diagnosed with @entity1150 alone (Group 2). The diagnosis was confirmed by duplex scanning in all @entity1 . In Group 1, there were 14 females (67%) and 7 males (23%) with ages ranging from 25 to 97 yr old [mean 73 yr old +/-17 yr (SD)]. In Group 2, there were 84 females (58%) and 60 males (42%) with ages ranging from 9 to 101 yr old [mean 67 yr old +/-17 yr (SD)]. Differences in age and sex between the two groups were not statistically significant. In Group 1, systemic anticoagulation was implemented in 17 @entity1 (81%). Two @entity1 (9.5%) required placement of a @entity6480 and IVC filters due to contraindication to anticoagulation. One @entity1 did not receive anticoagulation, and one @entity1 was only started on @entity117 . In Group 2, treatment consisted of systemic anticoagulation in 94 @entity1 (65%). The remainder of the @entity1 were treated with @entity117 in three @entity1 (2%) or no anticoagulation in 31 @entity1 (19%). Sixteen @entity1 (11%) underwent placement of a @entity6480 filter either due to failure of anticoagulation to prevent @entity1151 (two @entity1 ) or contraindication to anticoagulation (14 @entity1 ). Pulmonary emboli were documented by ventilation/perfusion lung scan in two @entity1 (9.5%) in Group 1 and in 16 @entity1 (11%) in Group 2. In the first group, 8 of the 21 @entity1 (38%) were dead within 1 month of the diagnosis of @entity1150 , and 11 of 21 @entity1 (52%) were dead within 2 months of the diagnosis of @entity1150 . In the second group, 20 of 144 @entity1 (14%) were dead within 1 month of the diagnosis of @entity1150 and 38 of 144 @entity1 (26%) were dead within 2 months of diagnosis (P<0.02). Our data suggest that @entity1 with both @entity1150 and @entity1150 have a higher mortality than @entity1 with @entity1150 alone. As the risk for @entity1151 is similar in both groups, we speculate that the severity of @entity221 in @entity1 with both @entity1150 and @entity1150 may contribute to the higher mortality. This is the first study to examine the mortality of this group of @entity1 .

Combined upper and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity6480 :: ('696863', 'Species') :: ['SVC'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['UEDVT', 'upper extremity deep venous thrombosis', 'LEDVT', 'lower extremity deep venous thrombosis'] @entity221 :: ('MESH:D005334', 'Disease') :: ['medical illness']
@entity1150 :: (MESH:D020246,Disease) :: ['lower extremity deep venous thrombosis']
